Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor

Dong, Renchao; Yang, Xiaobo; Wang, Changyuan; Liu, Kexin; Liu, Zhihao; Ma, Xiaodong; Sun, Huijun; Huo, Xiaokui; Fu, Ting; Meng, Qiang

doi:10.1016/j.phymed.2018.09.006

Cited by 31 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential underlying mechanism of Erchen decoction for the treatment of obesity, hyperlipidemia and fatty liver is to increase the CDKAL1 production, improve islet cell function and insulin level (Gao et al, 2015). A related study indicated that yangonin increased insulin sensitivity via increasing the expression of phosphorylated IRS-1 and IRS-2 (Dong et al, 2019).…”

Section: Insulin Signaling Pathwaymentioning

confidence: 97%

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application

Guo

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with high prevalence in the developed countries. NAFLD has been considered as one of the leading causes of cryptogenic cirrhosis and chronic liver disease. The individuals with obesity, insulin resistance and diabetes mellitus, hyperlipidaemia, and hypertension cardiovascular disease have a high risk to develop NAFLD. The related critical pathological events are associated with the development of NAFLD including insulin resistance, lipid metabolism dysfunction, oxidative stress, inflammation, apoptosis, and fibrosis. The development of NAFLD range from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic steatosis is characterized by fat accumulation, which represents the early stage of NAFLD. Then, inflammation triggered by steatosis drives early NAFLD progression into NASH. Therefore, the amelioration of steatosis and inflammation is essential for NAFLD therapy. The herbal medicine have taken great effects on the improvement of steatosis and inflammation for treating NAFLD. It has been found out that these effects involved the multiple mechanisms underlying lipid metabolism and inflammation. In this review, we pay particular attention on herbal medicine treatment and make summary about the research of herbal medicine, including herb formula, herb extract and naturals compound on NAFLD. We make details about their protective effects, the mechanism of action involved in the amelioration steatosis and inflammation for NAFLD therapy as well as the clinical application.

show abstract

Section: Insulin Signaling Pathwaymentioning

confidence: 97%

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application

Guo

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Yangonin was recently reported to protect against high-fat induced non-alcoholic fatty liver disease through the FXR in C57BL/6 mice [ 187 ]. Desmethoxyyangonin was also reported to protect against LPS/D-GalN-induced acute hepatic damage in mice [ 56 ].…”

Section: Safety Of Kava and Its Hepatotoxic Riskmentioning

confidence: 99%

Kava as a Clinical Nutrient: Promises and Challenges

et al. 2020

View full text Add to dashboard Cite

Kava beverages are typically prepared from the root of Piper methysticum. They have been consumed among Pacific Islanders for centuries. Kava extract preparations were once used as herbal drugs to treat anxiety in Europe. Kava is also marketed as a dietary supplement in the U.S. and is gaining popularity as a recreational drink in Western countries. Recent studies suggest that kava and its key phytochemicals have anti-inflammatory and anticancer effects, in addition to the well-documented neurological benefits. While its beneficial effects are widely recognized, rare hepatotoxicity had been associated with use of certain kava preparations, but there are no validations nor consistent mechanisms. Major challenges lie in the diversity of kava products and the lack of standardization, which has produced an unmet need for quality initiatives. This review aims to provide the scientific community and consumers, as well as regulatory agencies, with a broad overview on kava use and its related research. We first provide a historical background for its different uses and then discuss the current state of the research, including its chemical composition, possible mechanisms of action, and its therapeutic potential in treating inflammatory and neurological conditions, as well as cancer. We then discuss the challenges associated with kava use and research, focusing on the need for the detailed characterization of kava components and associated risks such as its reported hepatotoxicity. Lastly, given its growing popularity in clinical and recreational use, we emphasize the urgent need for quality control and quality assurance of kava products, pharmacokinetics, absorption, distribution, metabolism, excretion, and foundational pharmacology. These are essential in order to inform research into the molecular targets, cellular mechanisms, and creative use of early stage human clinical trials for designer kava modalities to inform and guide the design and execution of future randomized placebo controlled trials to maximize kava’s clinical efficacy and to minimize its risks.

show abstract

“…Convincing evidence indicates that overactivated hepatic gluconeogenesis and lipogenesis contribute to the pathogenesis of metabolic disorders, including DM and NAFLD. 3,4,15 Thus, precise control of hepatic gluconeogenesis and lipogenesis is important for maintaining metabolic homeostasis. PEPCK and G6Pase are the two key gluconeogenic enzymes that control hepatic gluconeogenesis.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of long non‐coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non‐alcoholic fatty liver disease

Huang

Zhi

et al. 2020

Cell Biochemistry & Function

View full text Add to dashboard Cite

Deregulated glucose and lipid metabolism are the primary underlying manifestations associated with diabetes mellitus (DM) and non-alcoholic fatty liver disease (NAFLD). This study aims to investigate the role of Gm10804, a novel long noncoding RNA (lncRNA), in regulating hepatic glucose and lipid metabolism in DM complicated with NAFLD (DM-NAFLD). Mouse primary hepatocytes exposed to high glucose (HG) were used as a cell model. A mouse DM-NAFLD model was established by high-energy feeding combined with intraperitoneal injection of streptozotocin. The results showed that Gm10804 expression was upregulated in HG-treated hepatocytes and livers from DM-NAFLD mice. Results in hepatocytes in vitro demonstrated that Gm10804 overexpression aggravated, whereas Gm10804 silencing abrogated HG-induced increase in intracellular triglyceride (TG) content, lipid accumulation and expression of hepatic lipogenic proteins (sterol regulatory element-binding proteins 1-c [SREBP-1c] and fatty acid synthase [FAS]) and enzymes for gluconeogenesis (phosphoenolpyruvate carboxykinase [PEPCK] and glucose-6-phosphatase [G6Pase]). Further in vivo assays showed that lentivirus-mediated hepatic knockdown of Gm10804 alleviated hepatic steatosis and lipid accumulation, and decreased expression of hepatic PEPCK, G6Pase, SREBP-1c and FAS in DM-NAFLD mice. In summary, Gm10804 knockdown attenuates hepatic lipid accumulation by ameliorating disorders of hepatic glucose and lipid metabolism in DM-NAFLD. Significance of the study: We first discovered that Gm10804 knockdown attenuated hepatic lipid accumulation by ameliorating disorders of hepatic glucose and lipid metabolism in DM-NAFLD. These results help to understand the pathogenesis and development of DM-NAFLD and provide some clues for further understanding the regulation of lncRNAs in glucose and lipid metabolism.

show abstract

Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor

Cited by 31 publications

References 25 publications

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application

Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application

Kava as a Clinical Nutrient: Promises and Challenges

Knockdown of long non‐coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non‐alcoholic fatty liver disease

Contact Info

Product

Resources

About